HIV: WHO recommends long-acting injectable cabotegravir

- Advertisement -

WHO has released new guidelines for the use of long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) for HIV and called for countries to consider this safe and highly effective prevention option for people at substantial risk of HIV infection.
The guidelines, released ahead of the 24th International AIDS Conference (AIDS 2022), will support countries as they plan for CAB-LA introduction as part of a comprehensive approach to HIV prevention and will facilitate urgently needed operational research.

The guidelines also note that young people and key populations often experience challenges in accessing current PrEP services. Communities must be involved in developing and delivering HIV prevention services that are effective, acceptable and support choice.

- Advertisement -


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.